Equities research analysts expect Xenon Pharmaceuticals Inc (NASDAQ:XENE) to report earnings of ($0.48) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Xenon Pharmaceuticals’ earnings, with estimates ranging from ($0.49) to ($0.47). Xenon Pharmaceuticals posted earnings of ($0.43) per share during the same quarter last year, which indicates a negative year over year growth rate of 11.6%. The firm is expected to report its next earnings report on Tuesday, May 8th.
On average, analysts expect that Xenon Pharmaceuticals will report full year earnings of ($1.28) per share for the current year, with EPS estimates ranging from ($1.34) to ($1.21). For the next year, analysts expect that the company will post earnings of ($1.69) per share, with EPS estimates ranging from ($1.88) to ($1.49). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.34). Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 65.72%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $6.38 million.
A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus upped their target price on shares of Xenon Pharmaceuticals from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday. ValuEngine downgraded shares of Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Finally, Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $6.33.
Xenon Pharmaceuticals (NASDAQ:XENE) opened at $4.50 on Friday. Xenon Pharmaceuticals has a 12-month low of $2.10 and a 12-month high of $9.95. The company has a debt-to-equity ratio of 0.17, a current ratio of 10.98 and a quick ratio of 10.99.
Large investors have recently made changes to their positions in the business. Sabby Management LLC increased its stake in Xenon Pharmaceuticals by 7.1% in the 4th quarter. Sabby Management LLC now owns 329,400 shares of the biopharmaceutical company’s stock worth $931,000 after acquiring an additional 21,800 shares during the last quarter. K2 Principal Fund L.P. lifted its holdings in shares of Xenon Pharmaceuticals by 33.5% in the 4th quarter. K2 Principal Fund L.P. now owns 219,543 shares of the biopharmaceutical company’s stock worth $620,000 after buying an additional 55,033 shares during the period. Finally, Renaissance Technologies LLC increased its position in Xenon Pharmaceuticals by 59.2% during the 4th quarter. Renaissance Technologies LLC now owns 249,000 shares of the biopharmaceutical company’s stock valued at $703,000 after buying an additional 92,600 shares in the last quarter. 50.90% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/03/12/brokerages-expect-xenon-pharmaceuticals-inc-xene-to-post-0-48-eps.html.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.